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Psoriasis is a chronic autoimmune skin disease that can often be triggered upon
skin injury, known as Koebner phenomenon. Type 1 interferons (IFNα and IFNβ), key
cytokines that activate autoimmunity during viral infection, have been suggested to
play an indispensable role in initiating psoriasis during skin injury. Type 1 IFN-inducible
gene signature has been identified as one of the major upregulated gene signatures
in psoriatic skin. Type 1 IFNs treatments often directly induce or exacerbate psoriasis,
whereas blocking type 1 IFNs signaling pathway in animal models effectively inhibits
the development of T cell-mediated skin inflammation and psoriasis-like inflammatory
diseases. Epidermal keratinocytes (KCs) occupy the outermost position in the skin and
are the first responder to skin injury. Skin injury rapidly induces IFNβ from KCs and
IFNα from dermal plasmacytoid dendritic cells (pDCs) through distinct mechanisms.
Host antimicrobial peptide LL37 potentiates double-stranded RNA (dsRNA) immune
pathways in keratinocytes and single-stranded RNA or DNA pathways in pDCs, leading
to production of distinct type 1 IFN genes. IFNβ from KC promotes dendritic cell
maturation and the subsequent T cell proliferation, contributing to autoimmune activation
during skin injury and psoriasis pathogenesis. Accumulating evidences have indicated an
important role of this dsRNA immune pathway in psoriasis pathogenesis. Together, this
review describes how skin injury induces type 1 IFNs from skin cells and how this may
initiate autoimmune cascades that trigger psoriasis. Targeting keratinocytes or type 1
IFNs in combination with T cell therapy may result in more sustainable effect to treat
auto-inflammatory skin diseases such as psoriasis.
Keywords: type 1 interferons, interferon beta, innate immunity, keratinocytes, inflammation, skin wounds,
psoriasis
INTRODUCTION
Skin, the largest organ of human body, functions as a physical and immunological barrier to protect
our bodies from external threats. The epidermis, positioned at the front line of defense, has evolved
to provide rapid and specific innate immune response that shapes the adaptive immune response,
leading to immediate as well as long term protection against physical dangers (1, 2). The barrier
function of epidermis is primarily provided by keratinocytes (KCs), the pre-dominant epidermal
cell type.While the physical barrier of the skin is maintained by a tightly controlled balance between
proliferation and differentiation of KCs (3, 4), the immunological barrier function of epidermis
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relies on rapid, precise and situation-specific innate immune
responses of KCs to insults. Psoriasis is considered as a T cell-
mediated autoimmune skin disease, whereas the role of KCs in
initiating the early upstream events in psoriasis has been under-
appreciated. In this review, we review current understanding
of immunopathology of psoriasis, the role of keratinocytes in
psoriasis initiation, and then emphasize on the role of type 1 IFNs
in linking innate immune activation upon skin injury and the
subsequent autoimmune amplification that leads to psoriasis.
PSORIASIS: ETIOLOGY,
IMMUNOPATHOGENESIS AND THERAPIES
Psoriasis is a chronic autoimmune skin disorder characterized
by well-demarcated, raised areas of erythematous plaques,
often covered by silvery scaling (5). It is estimated that
psoriasis affects 125 million people worldwide (∼1.7% of the
world population), including 2∼4% of the US or European
populations and ∼0.5% of the Asians (6). The three principal
histological features of psoriasis are hyperplastic/thickened
epidermis, elongated and increased vascularity in the dermis,
and inflammatory leukocyte infiltration (5). Beyond the lesions,
psoriasis is also associated with several comorbidities, such
as rheumatoid arthritis, atherosclerosis, cardiovascular diseases,
obesity, type 2 diabetics, Alzheimer’s disease, depression, and
non-melanoma skin cancer (7, 8). Increased disease burden
greatly impairs the quality of life in psoriasis patients.
A better understanding of psoriasis pathophysiology will
help to decipher the molecular alliance of psoriasis with
its comorbidities.
The etiology of psoriasis remains obscure. As shown in
Figure 1, besides genetic factors, several triggering factors
have been linked with an exacerbation of psoriasis, such as
infection, wound, obesity, stress, and drugs including beta-
blockers, lithium, interferons, and imiquimod (9–11). Innate
immune responses of resident keratinocytes or infiltrated
plasmacytoid dendritic cells (pDCs) are believed to play a
critical role in initiating the subsequent adaptive immune
events including dendritic cell (DC) maturation and T cell
activation (2, 12, 13). It has been shown that keratinocyte
or pDCs derived cytokines, such as IL1β and type 1 IFNs,
activate DC, which then stay local or travel to lymph nodes
and secrete cytokines TNFα, interleukin (IL)-12 and IL-
23, leading to type 1 T helper (Th1), and type 17 T helper
(Th17) cell activation, respectively (2, 14). Activated T cells
accumulate at the affected skin area, releasing additional
cytokines, such as IFNγ, TNFα, IL-22, and IL-17A (15). These
T cell derived cytokines recruit additional immune cells and
boost keratinocyte activation, leading to the initiation of a
self-propelled cycle of auto-inflammation and the ultimately
uncontrolled keratinocyte hyperproliferation and psoriatic
plaque formation (16, 17).
Preventing immune activation is the key to treat
psoriasis. Conventional psoriasis therapies, including general
immunosuppressive therapies (such as topical corticosteroids
and systemic methotrexate or cyclosporin therapies), vitamin
D analogs, topical retinoids, and UVB phototherapy, are
associated with broadband immunosuppression and/or organ
toxicities that can be problematic when used long term (18).
New biological drugs against specific immunological elements
have gained popularity as safe and effective alternatives to
treat moderate to severe plaque psoriasis. These biological
drugs including monoclonal antibodies against TNFα (such
as etanercept and infliximab), IL12 (such as Ustekinumab),
IL23 (such as Guselkumab and Tildrakizumab), IL-17A
(such as Secukinumab and Ixekizumab), or IL17AR (such as
Brodalumab) have shown clinical efficacy in improving skin
conditions in clinical trials and most of these drug are already
on the market (9, 19–21). However, relapse of the disease
shortly after drug withdrawal is one of the major obstacles for
these DC or T-cell targeted therapies in clinical trials (22–25),
suggesting that preventing adaptive immune activation alone
is not sufficient to treat psoriasis. A better understanding
of the innate immune mechanisms initiating psoriasis is
urgently needed to develop novel therapeutic approach to
treat psoriasis.
KOEBNER PHENOMENON, FROM SKIN
WOUND TO PSORIASIS
The initial onset of psoriasis is often followed by chronic relapses
of the disease triggered by wounding, infections and mechanical
stress (5). In 1876, Hinrich Koebner, MD, first described the
development of psoriatic lesion after physical trauma such as
tattoos, horse bites, and wounds. Later, “Koebner phenomenon”
has been used to describe the formation of isomorphic lesions
on healthy skin following a cutaneous trauma (e.g., wounds,
burns, or surgical incisions) and it is now not restricted to
psoriasis but applies to many other skin conditions, such as
lichen planus, vitiligo, and lupus erythematosus. Dermal pDCs, a
rare population of circulating cells specialized in the production
of type 1 IFNs, is thought to be one of the earliest events in
psoriasis pathogenesis and subsequently primes the innate and
adaptive immune system (12, 26). While dermal pDC activation
in wounded skin may partially explain Koebner phenomenon,
it is still unclear why even superficial tattoos can trigger the
pathogenesis of psoriasis. An epidermal mechanism is likely
to play a role in the development of a Koebner reaction in
psoriatic patient.
KERATINOCYTES UNDER FIRE OF
PROINFLAMMATORY CYTOKINES
Keratinocytes, constituting ∼90% of the epidermal cells,
are poised directly at the interface with the external
environment, depositing them as the first responder to
skin injury. Recent studies have established the essential
role of keratinocytes in psoriasis initiation. Rapid innate
immune responses of keratinocytes, to a variety of external
stimuli, leads to production of an array of pro-inflammatory
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FIGURE 1 | The interplay between innate and adaptive immune cells in the pathogenesis of Psoriasis. Psoriasis can be triggered by several factors, including genetic
variants, infection, wound, obesity, stress, and drugs. Early upstream events in psoriasis involve the innate immune activation of skin resident keratinocytes or
fibroblasts or recruited plasmacytoid dendritic cells (pDCs) or neutrophils. Cytokines derived from these innate immune cells promote myeloid dendritic cell maturation,
with consequent Th17 T cell development and the beginning of the adaptive immune phase. T cell infiltrate promotes inflammatory amplification of innate immune
cells, leading to the formation of an autoimmune self-amplifying loop that drives pathogenic hyperproliferation of keratinocytes and manifestations of psoriasis.
cytokines or chemokines such as IFNβ, IL1β, IL36,
TNF, IL6, IL8, IL25, and CXCL10 (2, 27–29). These
keratinocyte-derived cytokines prime epidermal innate
immune signals with dermal adaptive immune system,
contributing to autoimmune activation and psoriasis
pathogenesis (2, 3, 27, 28, 30, 31).
The inflammatory T cell phenotype of psoriasis can be
initiated by altering innate immune system of keratinocytes
in mice. For example, epidermal specific deletion of IKK2
(inhibitor of nuclear factor κB) (32) or c-JUN (33) or
epidermal specific overexpression of Tie2 (34) or IL17C
(35) or the active form of STAT3 (36) or IL25 (29) lead
to spontaneous keratinocyte activation and cytokine release
followed by the development of psoriasis-like skin inflammation.
Recent study from Kabashima’s group shows that conditional
deletion of TRAF6 in keratinocytes abrogates DC activation,
IL-23 production, and the subsequent IL-17 mediated psoriatic
inflammation in the imiquimod psoriasis mouse model (37).
Our group have found that induction of IFNβ from KC is one
of the earliest innate immune events during skin injury (2).
Keratinocyte-derived IFNβ promotes dendritic cell maturation
and the subsequent T cell proliferation, leading to psoriatic
inflammation development (2). These studies suggest that innate
immune responses of keratinocytes are essential to initiate
the autoimmune cascade and drive psoriasis pathogenesis,
and type 1 IFNs may function as an early initiating factor
linking skin wounds with adaptive immune activation that
drives psoriasis.
TYPE 1 IFNS AND
AUTOIMMUNE DISEASES
Type 1 interferons (IFNs) belong to the class II family of
cytokines, which is composed of 16 members, including 13
IFNα subtypes, IFNβ, IFNε, IFNκ, and IFNω (38). Among these
type 1 IFNs, IFNα, and IFNβ are the most extensively studied.
Type1 IFNs were first discovered more than 60 years ago as
the key factors induced upon viral infection, owing to their
ability to limit viral replication and promote immune activation
(39–41). And now type 1 IFNs have been recognized as the
central cytokines that link innate immunity with autoimmune
activation during pathogenesis of several systemic autoimmune
diseases and several organ-targeted inflammatory diseases (42,
43). Systemic lupus erythematosus (SLE) is the most well-studied
autoimmune disease driven by type1 IFNs (42), and recent
studies have also demonstrated pathogenic role of type 1 IFN
in psoriasis, rheumatoid arthritis, diabetes mellitus, Sjogrens
syndrome, dermatomyositis (DM), and systemic sclerosis (38,
44–46). SLE and psoriasis share many similar clinical features
and can both be triggered by infection, wounding or type1 IFNs,
and Th17T cells contribute to pathogenesis of both diseases.
However, SLE is characterized by overproduction of a wide array
of autoantibodies and is therefore traditionally classified as a
“B-cell disease” (47), whereas B cell contribution to psoriasis
remains unclear. Distinct susceptible genes have been identified
for SLE and psoriasis (6, 48), suggesting that genetic factors
may contribute differential adaptive immune development in
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response to type 1 IFNs, leading to distinct disease manifestation
in SLE and psoriasis.
TYPE 1 IFNS AND
PSORIASIS PATHOGENESIS
Type 1 IFNs are associated with psoriasis. Psoriasis is often
triggered by chronic viral infections or wounding, and type 1
IFNs as the key cytokines induced upon these conditions (49,
50). Clinically, type 1 IFNs treatments in patients with viral
infection or multiple sclerosis (MS) often directly induce or
exacerbate psoriasis or psoriasis arthritis (50–53). Furthermore,
transcriptome analyses have identified type 1 IFN pathway genes
as one of the top upregulated gene signatures in psoriatic skin,
outscoring the upregulation of TNFα pathway gene signature
(54–56). Immunostaining analyses have shown that while IFNα
is pre-dominantly produced by dermal infiltrated pDCs, IFNβ
expression is rapidly induced in epidermal keratinocytes as early
as 1 day post-wounding and in psoriatic epidermis compared to
normal human skin (2, 12, 13).
In line with these clinical observations, type 1 IFN pathway
is also necessary for the development of T cell-mediated
skin inflammation and psoriasis-like inflammatory diseases in
mice. Mice treated with IFNα or IFNβ neutralizing antibodies,
or mice lacking IFNAR (receptor for IFNα/β) failed to
develop Th17 cell-mediated skin inflammation (12, 13). Fuchs’s
group shows that UV alleviates the imiquimod (IMQ)-induced
psoriatic inflammation by downregulating IFNAR1 expression
in keratinocytes (57). IMQ-induced psoriatic inflammation was
blocked in Ifnar deficient (Ifnar−/−) mice, and in contrast
IfnarSA mice (in which Ifnar ubiquitination and degradation
was blocked) exhibited exacerbated inflammatory response to
IMQ compared to wildtype controls (57), demonstrating that
IFNAR plays a critical role in promoting the development of
psoriasis like inflammation in mice. In addition, mice deficient
for interferon regulatory factor 2 (Irf 2), the transcriptional
attenuator of IFNα/β signaling, developed spontaneous psoriasis-
like inflammatory disease (58). Type 1 IFNs upregulates the
expression of IL22 receptor in keratinocytes, leading to an
increase in keratinocytes’ responsiveness to IL22, which drives
Stat3 phosphorylation and keratinocyte hyperproliferation (15).
Our group has also shown that IFNβ from activated human or
mouse keratinocytes can directly promote cDC (conventional
dendritic cell) maturation and the subsequent T cell proliferation
in vitro (2). These collective evidences support that type 1 IFNs
play an essential role in initiating skin inflammation during
psoriasis pathogenesis.
In addition to its proinflammatory role, type 1 IFNs may
also regulate keratinocyte differentiation. In both normal and
psoriatic skin epidermis, IFNβ expression is restricted to KCs at
the differentiated cell layers (2, 59, 60), and IFNβ is expressed
by growth arrested or differentiated KCs but not by dividing
KCs in vitro (59). Neutralizing IFNβ in culture medium inhibited
differentiation, but addition of exogenous IFNβ did not stimulate
differentiation or alter proliferation (59). Future studies are still
needed to determine whether IFNβ expression in differentiated
KCs is a consequence or the cause of KC cell arrest and/or
differentiation, and to determine whether IFNβ contributes to the
aberrant proliferation and differentiation in psoriasis.
DISTINCT CELLULAR SOURCE OF IFNα
AND IFNβ IN PSORIASIS
IFNα and IFNβ are produced by distinct cellular sources in
wounded and/or psoriatic skin. Upon skin injury, pDCs rapidly
infiltrate the skin, sense nucleic acid released from damaged
cells, then produce large quantity of IFNα, which then initiates
the autoimmune cascade (12, 13) (Figure 2). Activation of pDC
precedes cDC or T cells activation (12), suggesting IFNα from
pDC may play a role during early phase of disease progression.
Our group has shown that while IFNα is primarily produced
by pDC in the dermis, IFNβ is pre-dominantly produced by
epidermal keratinocytes in skin wounds or psoriasis (2). Direct
comparison of in vitro activated KCs and pDCs revealed that
while KCs lack the ability to produce IFNα upon activation,
activated KCs produce higher amount of IFNβ compared to
activated pDCs (2). Secretion of IFNβ from keratinocytes
promotes activation and maturation of classical dendritic cells,
leading to the subsequent T cell proliferation and autoimmune
amplification (2). Furthermore, keratinocyte-derived IFNβ can
also promote pDCmaturation and activation (2), suggesting that
keratinocytes might also contribute to pDC activation during
early phase of skin injury. Together, these findings suggest that
KCs are an active source of IFNβ and can participate with
pDCs to prime the adaptive immune system during psoriasis
pathogenesis (Figure 2).
REGULATION OF TYPE1 IFNS
EXPRESSION BY PATTERN
RECOGNITION RECEPTORS
Type 1 IFNs are known to be induced by a variety of
DAMPs (damage associated molecular patterns) or PAMPs
(pathogen associated molecular patterns) in either through Toll-
like receptor (TLR)-dependent or TLR-independent pathways
(38, 61) in a cell type specific manner. Type1 IFNs can be induced
upon activation of endosomal TLR7 and 9 or cytosolic cGAS-
STING (cyclic GMP-AMP synthase-stimulator of interferon
genes) by host or viral or bacterial DNA, endosomal TLR8
by ssRNA, endosomal TLR3 or mitochondrial RIG1 (retinoic
acid-inducible gene 1) -MAVS (mitochondrial antiviral-signaling
protein) by host or viral dsRNA, or plasma membrane TLR4
by bacterial LPS (38, 61). The cell responsiveness to various
DAMPs or PAMPs relies on the expression of pattern recognition
receptors (PRRs). pDCs express high levels of TLR7 and TLR9,
therefore pDC can rapidly sense self-DNA released upon injury
then produce IFNα (13, 26, 39). While TLR4 and TLR8 are
usually not expressed in pDC, these PRRs are highly expressed
in classical DC or monocytes (62), making these cells highly
responsive to bacterial LPS or self-RNA. In contrast to these
myeloid derived immune cells, keratinocytes express high levels
of TLR3 and MAVS, but not TLR4, 7, 8, or 9 (2, 30, 31).
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FIGURE 2 | The role of type 1 interferons in initiating psoriatic inflammation during skin injury. During skin injury (known as Koebner phenomenon), damaged
keratinocytes (dKC) release self-nucleic acids, including dsRNA, ssRNA, and DNA. Antimicrobial peptide LL37, which is transiently induced in KC upon wounding
enables dsRNA recognition by MAVS and TLR3 in KC, leading to activation of the pAKT-pTBK1-pIRF3 signaling cascade and the subsequent transcription initiation of
the IFNB1 gene from activated KCs (aKC). LL37 can also enables ssRNA or DNA recognition by TLR7 or 9 in pDCs, leading to transcription of IFNA family genes.
Type 1 IFNs, including IFNβ from KC and IFNα from pDCs, promote maturation of conventional DCs (cDCs). Activated DCs produce IL23, promoting the development
of Th17 and Th22 autoimmune T cells, which in turn act on keratinocytes, leading to epidermal hyperplasia and psoriasis pathogenesis. dsRNA, double-stranded
RNA; ssRNA, single-stranded RNA; MAVS, Mitochondrial Antiviral Signaling Protein; TBK1, TANK-Binding Kinase 1; IRF3, interferon regulatory factor 3.
Therefore, keratinocytes rapidly produce IFNβ in response to
dsRNA but not to TLR4, 7, 8, or 9 ligands (2). We have
showed that, wounded keratinocytes upregulate the expression
of antimicrobial peptide LL37, which then enables MAVS and
TLR3 in keratinocytes to recognize dsRNA released from dying
cells (2). By MAVS-dependent activation of TBK1 (TANK-
Binding Kinase 1)-AKT (AKT serine/threonine kinase 1)-IRF3
(interferon regulatory factor 3) signaling pathway, keratinocytes
produce and secrete IFNβ (2). Keratinocyte-derived IFNβ then
promotes DC maturation and the subsequent T cell activation
to facilitate the development of an autoimmune cutaneous
inflammatory response (2). These results show that the cell
type specific expression of pattern recognition receptors shape
the unique and situation specific innate immune response of
these cells.
ROLE OF DSRNA SIGNALING IN
PSORIASIS PATHOGENESIS
Recent studies have suggested an important role for dsRNA
in autoimmune initiation during psoriasis pathogenesis.
Extracellular RNA complexes have been found in psoriatic skin
(62), and dsRNA is also detected in the cytosol of wounded or
psoriatic KCs while it is normally localized in the nucleus of
KCs in normal skin (2). Recently, it has been shown that the
dsRNA accumulation in psoriatic keratinocytes is associated
with impaired A-to-I RNA editing activity, which is essential
for post-translational modification of dsRNA and unwinding
of dsRNA structures (63). In line with these observations,
functional analysis of the psoriasis susceptible gene implicates
the involvement of innate immune responses to dsRNA in
disease progression (64).
Accumulating evidences have demonstrated that dsRNA can
be released as a DAMP by damaged cells or a PAMP by invading
viruses to initiate host immune activation. We and others
have shown that dsRNA released by tissue damage activates
and TLR3 and it is required for normal inflammation or skin
regeneration (30, 65). Viral dsRNA or endogenous dsRNA (such
as U1 RNA) released upon injury acts on keratinocytes through
the mitochondrial MAVS pathway to produce IFNβ, leading to
adaptive immune activation (2, 31, 66). Skin injury or infection
strongly induces the expression of cathelicidin antimicrobial
peptide expression in KCs (2, 67), and LL37 (the α-helical
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polypeptide derived from cathelicidin) forms pro-inflammatory
nanocrystalline complex with dsRNA that potentiates pattern
recognition receptor clustering and immune amplification (2,
68). Together these recent evidences have shown that dsRNA
released upon infection or injury may synergize with the host
antimicrobial peptide to initiate the autoimmune activation in
psoriasis, and this dsRNA immune response in keratinocytes may
explain the Koebner phenomenon and why viral infection and
wounding triggers psoriasis.
TARGETED THERAPIES FOR PSORIASIS:
CURRENT STATUS AND
FUTURE DEVELOPMENTS
Psoriasis is not just a T cell mediated disease. New biological
drugs targeting the TNF/IL-23/IL-17 pathways have shown to be
safe and efficacious in recent psoriasis clinical trials (9, 19, 20).
However, potential problems including lack of long term efficacy
and rapid regain of psoriasis upon drug removal (22, 23, 25)
suggest that inhibiting T cell activation is only effective to
alleviate the disease symptoms but it cannot cure the disease.
If the initiating factors such as type 1 IFNs are still active, and
these factors can quickly re-initiate the inflammatory cascade
and reactivate pathogenic T cells upon withdrawal of the T cell
targeted therapy. In addition, studies has suggested that cytokines
including type 1 IFNs, TNF, and IL17, are interwoven, and each
of these cytokines is the cornerstones of an inflammatory triangle
that drives the development and maintenance of psoriasis (69).
Targeting one of these cytokines may affect the others. For
example, patents treated with TNF blocking agents sometimes
develop paradoxical psoriasis and this is resulted from an
overproduction of IFNα from pDCs upon TNF inhibition (70–
72). Together, these clinical observations indicate that inhibiting
activation of the innate immune system of KCs or pDCs that
initiates the autoimmune cascade may be needed in addition to
targeted T cell therapy to prevent reoccurrence of the disease
upon drug withdrawal. TargetingMAVS orTLR3 in KC to prevent
IFNβ production from the skin epidermis is of great potential for
future targeted therapy development to treat psoriasis.
CONCLUSION
Located at the skin surface, keratinocytes are constantly
exposed to a variety of stimuli, and can secrete an array of
cytokines, which function as secondary messengers connecting
the innate immune with adaptive immune system. Type 1
IFNs, which are the essential mediator of autoimmunity and
antivirus host defense, have emerged as an important initiating
element in the immunopathology of autoimmune cascade
and psoriasis. In contrast to dermal pDC which produce
IFNα in response to ssRNA or DNA, keratinocytes express
high levels of MAVS and TLR3 and therefore can sense
self-dsRNA in the presence of antimicrobial peptide and to
produce IFNβ. Production of Type 1 IFNs from these innate
immune cells upon skin injury may explain the Koebner
phenomenon, and this may also explain psoriasis triggered
by other factors such as bacterial or viral infections as RNA
or DNA released from pathogens will activate similar innate
immune response. Future studies will be needed to develop
targeted therapy to block the innate immune activation of these
PRRs in keratinocytes, which may result in more sustainable
interventions to treat psoriasis in addition to current T cell
targeted therapies.
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